Skip to main content
SpringerLink
Log in

Alvimopan

ADL 8-2698, ADL 82698, Entrareg, LY 246736

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Adolor Corporation, GlaxoSmithKline. Adolor and Glaxo-SmithKline announce worldwide development and commer-cialization agreement for alvimopan. Media Release: 15 Apr 2002. Available from URL: http://www.adolor.com

    Google Scholar 

  2. Adolor Corporation. Adolor Reports Initial Results from GSK European Phase 3 Study of Alvimopan. Media Release: 23 Dec 2004. Available from URL: http://www.adolor.com

    Google Scholar 

  3. Adolor Corporation. Adolor Submits First Portion of NDA for Entereg(TM) (alvimopan) in Postoperative Ileus. Media Release: 7 May 2004. Available from URL: http://www.adolor.com

    Google Scholar 

  4. Adolor Corporation. Adolor Completes Submission of NDA for Entereg (TM) (alvimopan) in Postoperative Ileus. Media Release: 28 Jun 2004. Available from URL: http://www.adolor.com

    Google Scholar 

  5. Adolor Corporation. FDA Extends PDUFA Action Date for Entereg(TM) (alvimopan) Capsules to July 25, 2005. Media Release: 19 Apr 2005. Available from URL: http://www.adolor.com

    Google Scholar 

  6. Adolor Corporation. Adolor Receives FDA Approvable Letter for Entereg(R) (Alvimopan). Media Release: 22 Jul 2005. Available from URL: http://www.adolor.com

    Google Scholar 

  7. Adolor Corporation. Adolor Announces FDA Update. Media Release: 10 Jan 2005. Available from URL: http://www.adolor.com

    Google Scholar 

  8. Adolor Corporation, GlaxoSmithKline Corporation. Adolor and GlaxoSmithKline Report Positive Top-Line Results in Phase 3 Study 314 of Entereg(R) (Alvimopan) in Postoperative Ileus. Media Release: 7 Feb 2006. Available from URL: http://www.adolor.com

    Google Scholar 

  9. Adolor Corporation. Adolor Corporation Announces Top-Line Results in Entereg(TM) Phase 3 Clinical Study 308 in Postop-erative Ileus. Media Release: 13 Jan 2004. Available from URL: http://www.adolor.com

    Google Scholar 

  10. Adolor Corporation. Adolor Corporation Announces Top-Line Results In Phase 3 Safety Study of Entereg(TM) (alvimopan) in Postoperative Ileus. Media Release: 22 Oct 2003. Available from URL: http://www.adolor.com

    Google Scholar 

  11. Adolor Corporation. Adolor Corporation Receives Patents Covering Novel Uses and Compositions Containing Alvimopan. Media Release: 13 Nov 2002. Available from URL: http://www.alolor.com

    Google Scholar 

  12. Zimmerman DM, Gidda JS, Cantrell BE. LY246736 dihydrate: mu opioid receptor antagonist. Drugs of the Future 19: 1078–1083, Dec 1994

    Google Scholar 

  13. Adolor Corporation. Adolor Corporation completes phase 2 clinical trials in post-operative ileus second phase 3 pivotal clinical trial to begin shortly. Media Release [3 pages], 28 Jun 2001. Available from URL: http://www.adolor.com

    Google Scholar 

  14. Adolor Corporation. Adolor Corporation Announces Topline Results of Alvimopan Phase 3 Study in Opioid Bowel Dysfunction. Media Release: 11 Nov 2002. Available from URL: http://www.adolor.com

    Google Scholar 

  15. Adolor Corporation. Adolor Announces Top-Line Results of Alvimopan Phase 3 Clinical Study. Media Release: 2 Apr 2003. Available from: URL: http://www.adolor.com

    Google Scholar 

  16. Adolor Corporation. Adolor Corporation Announces Positive Top-Line Results in 2nd Phase 3 Study of Alvimopan in Postoperative Ileus. Media Release: 23 Sep 2003. Available from URL: http://www.adolor.com

    Google Scholar 

  17. Adolor Corporation, GlaxoSmithKline. Data Published from Entereg(TM) (alvimopan) Phase 3 Clinical Trial in Annals of Surgery. Media Release: 23 Sep 2004. Available from URL: http://www.adolor.com

    Google Scholar 

  18. Zimmerman DM, Gidda JS, Cantrell BE. Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxy-phenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. Journal of Medicinal Chemistry 37: 2262–2265, 22 Jul 1994

    Article  PubMed  CAS  Google Scholar 

  19. Liu SS, Hodgson PS, Carpenter RL, et al. ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clinical Pharmacology and Therapeutics 69: 66–71, Jan 2001

    Article  PubMed  CAS  Google Scholar 

  20. Adolor Corporation. Adolor Corporation successfully completes two phase 2 clinical trials of ADL 8-2698 in opioid induced bowel dysfunction — plans to begin phase 3 clinical trials. Media Release [3 pages], 18 Jan 2001. Available from URL: http://www.adolor.com

    Google Scholar 

  21. GlaxoSmithKline, Adolor Corporation. GlaxoSmithKline and Adolor Present Positive Results From a Clinical Study of alvimopan (Entereg(R)). Media Release: 4 May 2006. Available from URL: http://www.gsk.com

    Google Scholar 

  22. LY 246736 speeds postoperative recovery of intestinal function. Inpharma 1308: 8, 6 Oct 2001

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alvimopan. Drugs in R D 7, 245–253 (2006). https://doi.org/10.2165/00126839-200607040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200607040-00004

Keywords

Search

Navigation